Navigation Links
Huiheng Medical, Inc. Reports Record Financial Results for Fiscal Year 2007 and Financial Results for Q1 2008
Date:5/16/2008

ompared to $6.61 million for the same period of the prior year. This increase in unit sales in 2007 was due to an increased demand in the market for our radiotherapy products.

Total revenues from services were $5.04 million in 2007, an increase of $0.36 million or 7.7%, compared to $4.68 million in 2006. The increase was due to the signing of 3 new service contracts in mid-2006 which resulted in revenues on those contracts for roughly half of 2006 and all of 2007.

Total revenues from tax refunds and subsidies were $1.38 million in 2006, an increase of approximately $320,000 or 30% over the $1.06 million in tax refunds and subsidies for 2007. Tax refunds and subsidies accumulate each current year and are paid and recognized as revenue the following year.

Cost of revenues

The total cost of revenues in 2007 amounted to $3.76 million, an increase of $1.11 million or 41.9%, compared to $2.65 million in 2006. The increase was due to increased number of units sold in 2007 compared with 2006.

Gross margin

As a percentage of total revenues, the overall gross margin in 2007 decreased to 76.4% from 78.5% in 2006. The decrease was due to product sales accounting for a larger percentage of total revenues in 2007 compared with 2006, when higher margin service revenues accounted for a larger percentage of total revenues.

Operating expenses

Sales and marketing expenses. Sales and marketing expenses were approximately $82,000 in 2007, a decrease of 33%, or roughly $41,000 compared to approximately $123,300 in 2006. The decrease was due to a fewer commissions paid to sales staff as senior management was responsible for several sales and were not paid any commissions.

General and administrative expenses. General and administrative expenses were $1.53 million in 2007, an increase of roughly $250,000 compared to approximately $1.28 million in 2006. The increase in general and administrative expenses was due primarily to incr
'/>"/>

SOURCE Huiheng Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Medical, technological advances prompt updating of nuclear medicine technologists scope of practice
2. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
3. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
4. Thermage, Inc. Announces Distribution Agreement With Eclipse Medical, Ltd.
5. Medical, Behavioral Woes Can Drive Dogs to Bite
6. ReBuilder Medical Technologies, Inc. Announces UK Demand for Safe Molluscum Contagiosum Treatment Leads to Distribution Agreement with UFFE Medical, LTD. Expected 10% Sales Increase.
7. Sedgwick CMS and UnitedHealth Group to Develop Integrated Disability, Medical, Workers Compensation and Leave Administration Services for Employers
8. Emmaus Medical, Inc. Enters Into Sub-License Agreement for Treatment of Short Bowel Syndrome
9. XCPT(TM) Patient Engagement and Communication Software Signs Representation Agreement with Lifecore Biomedical, Inc. (Nasdaq: LCBM)
10. Gary Tschautscher of Nonin Medical, Inc. Receives CEO of 2007 for North American Patient Monitoring From Frost & Sullivan
11. Cardiva Medical, Inc. Appoints Two New Officers: Malcolm Farnsworth as Vice President of Finance and Chief Financial Officer and Tara Zerby as Vice President of Business Development and Marketing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2008)...Ind., Aug. 29 /PRNewswire/ -- Conseco Insurance Co...announced the availability of its new,indexed uni... The policy,provides upside potential with downsid...niversal life policy that offers the,opportunity f...m index,credit of 1%. Clients can customize their ...
(Date:8/29/2008)...Va., Aug. 29 /PRNewswire-USNewswire/ -- The Custom...d today the launch of the Endocrine,Daily Briefing...tigious,Endocrine Society., Endocrine Daily Brief...0 Endocrine Society members, medical professionals...betes and osteoporosis. Endocrine Daily,Briefing j...
(Date:8/29/2008)...ates disappointed that Obama failed to address the...- Speaking at the Democratic,National Convention W...ed,for a reinvigorated response to the domestic HI...Presidential nominee Barack Obama, Clinton said,"...ble global leadership in,an area in which I am dee...
(Date:8/29/2008)...ON, Aug. 29 /PRNewswire-USNewswire/ -- The followi...Campaign for Tobacco-Free Kids:, For the second t...d to,withdraw sponsorship and promotion of a conce...rnational criticism for engaging in cigarette,mark...p Morris International has been forced to withdraw...
Breaking Medicine News(10 mins):Health News:ConsecoLifeOptions Launched by Conseco Insurance Company as New Universal Life Product 2Health News:Custom Briefings Announces Launch of Endocrine Daily Briefing 2Health News:Bill Clinton and Other Leaders Call For 'Renewal of Battle Against AIDS' in the United States at Democratic Convention 2Health News:Bill Clinton and Other Leaders Call For 'Renewal of Battle Against AIDS' in the United States at Democratic Convention 3Health News:Philip Morris International Forced to Drop Another Concert Sponsorship; Philippines Health Department Applauded for Taking Action 2
...s suffering from tennis elbow ask them to alter th....// A new study evaluating the muscle firing patte... no bearing on the development of tendonitis. Res...p" on the relationship between the development of ...
...has made public its plan of enforcing a ban on smo...ices, cinemas, factories, pubs, bars and such othe... ban.// But the ban does not include outdoors or p...s in England will be required to put up visible “N...
...ey 2005-06 has revealed the extent of spousal viol... injustice meted out to unmarried women. The surve... f 30 organizations who were involved in accumulat...ment in certain categories. Fred Arnold, Vice-Pres...
... needed, especially into the possible genetic and ... in Bhopal exactly// 22 years ago that killed more... subsequent years. Despite the neurological, horm...he survivors are facing besides the genetic damage...
Other Medicine News:Health News:Tennis Elbow is Not Caused Due to Improperly Sized Tennis Racket Grip 2Health News:Tennis Elbow is Not Caused Due to Improperly Sized Tennis Racket Grip 3Health News:Children of Bhopal Gas Victims Suffer from Deformity 2Health News:Children of Bhopal Gas Victims Suffer from Deformity 3
(Date:8/27/2008)...ust 27 /-, - Oralair(R) Gr...Pharmacodynamic Study Conducted in an Allergen Cha...ighly positive results of a new study,conducted in...on Oralair(R) Grasses included 86 adult patients e...eatment durations: 1 week, 1 month,2 and 4 months...
(Date:8/26/2008)...6 /- The Oregon Tourism Commission,la...ervice Training Program,(Q Care) this week on htt...ining program created to support the tourism and,h...ation. By emphasizing,the importance of quality cu...with tools and resources to better serve Oregon,s ...
(Date:8/26/2008)...26 /- Semafore Pharmaceuticals Inc.,p...s on Targeted Therapies,in Cancer in Washington, D...ted kinase inhibitors that demonstrate significant...ovel and proprietary molecular scaffold has been d... the design of pan-PI3 kinase inhibitors,as well a...
(Date:8/26/2008)... 26 /- Cambridge Research &,Instrumen...estro(TM) EX In,Vivo Imaging System. The new syste...ogy and becomes the entry-level instrument of choi...tp://www.newscom.com/cgi-bin/prnh/20080826/NETU054...ancement of CRi,s unique,solid-state tunable optic...
Breaking Medicine Technology:Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber 2Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber 3Oregon Tourism Commission Unveils New Online Customer Service Training Program 2Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 2Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 3CRi Announces New Maestro(TM) EX In Vivo Imaging System with Improved Performance and an Affordable Price 2Hormonal Changes and Depression 3A What is the Connection 3F 6212 1Hormonal Changes and Depression 3A What is the Connection 3F 6212 2Hormonal Changes and Depression 3A What is the Connection 3F 6212 3Hormonal Changes and Depression 3A What is the Connection 3F 6212 4Telomerase enzyme structure provides significant new target for anti cancer therapies 6207 1Telomerase enzyme structure provides significant new target for anti cancer therapies 6207 2Telomerase enzyme structure provides significant new target for anti cancer therapies 6207 363 percent of diabetics risk serious foot problems by wearing the wrong sized shoes 6202 163 percent of diabetics risk serious foot problems by wearing the wrong sized shoes 6202 2How much fish have we got 3F 1202 1How much fish have we got 3F 1202 2How much fish have we got 3F 1202 3
...primary and secondary endpoints of,study; no negat...opicitabine and ribavirin ~, CAMBRIDGE, Mass., Jun...ceuticals, Inc. today announced results from a pha...n therapy, consisting of,valopicitabine (NM283), I...epatitis C, pegylated interferon and ribavirin,com...
...07 /PRNewswire/ -- Accera, Inc.,today is presentin...Ib clinical trial of AC-1202 (Ketasyn) in Alzheime...International Conference on,Prevention of Dementia...of earlier clinical and preclinical studies, AC-12...ve the memory and,cognition of subjects of a parti...
Other Medicine Technology:Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 2Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 3Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 4Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 5Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 6Accera, Inc. Announces Open-Label Data from Phase II Study in,Alzheimer's Disease at International Conference on Prevention of,Dementia 2Accera, Inc. Announces Open-Label Data from Phase II Study in,Alzheimer's Disease at International Conference on Prevention of,Dementia 3Accera, Inc. Announces Open-Label Data from Phase II Study in,Alzheimer's Disease at International Conference on Prevention of,Dementia 4
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value.
Amvex offers a complete line of flowmeters, available in oxygen, air, heliox and CO 2 . They are all available in a variety of calibrations to best suit your application. With color coded labels and
Amvex offers a complete line of flowmeters, available in oxygen, air, heliox and CO 2 . They are all available in a variety of calibrations to best suit your application. With color coded labels and
Amvex offers a complete line of flowmeters, available in oxygen, air, heliox and CO 2 . They are all available in a variety of calibrations to best suit your application. With color coded labels and
Medicine Products: